Brief: Health Canada Clears Appili Therapeutics For New Phase 3 Clinical Trial To Evaluate Avigan Tablets In The Prevention Of Covid-19

Appili Therapeutics

24/11/2020 12:23

Nov 24 (Reuters) - Appili Therapeutics Inc  APLI.TO :
    * HEALTH CANADA CLEARS APPILI THERAPEUTICS FOR NEW PHASE 3
CLINICAL TRIAL TO EVALUATE AVIGAN TABLETS (FAVIPIRAVIR) IN THE
PREVENTION OF COVID-19 IN EXPOSED INDIVIDUALS IN THE COMMUNITY
    * APPILI THERAPEUTICS - SIGNS AGREEMENT WITH CRO AND FILES
PHASE 3
CLINICAL TRIAL PROTOCOL WITH FDA IN ADVANCE OF ANTICIPATED STUDY
INITIATION IN U.S.
    * APPILI THERAPEUTICS - DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED STUDY WILL INCLUDE APPROXIMATELY 1,156
PARTICIPANTS IN U.S. AND CANADA
    * APPILI THERAPEUTICS - EXPECTS ENROLLMENT TO BEGIN EARLY
2021

Source text for Eikon:  ID:nBw5qcW39a 
Further company coverage:  APLI.TO 

 ((Reuters.Briefs@thomsonreuters.com;))